| Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial J Zajicek, P Fox, H Sanders, D Wright, J Vickery, A Nunn, A Thompson The lancet 362 (9395), 1517-1526, 2003 | 1026 | 2003 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 939 | 2018 |
| Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up JP Zajicek, HP Sanders, DE Wright, PJ Vickery, WM Ingram, SM Reilly, ... Journal of Neurology, Neurosurgery & Psychiatry 76 (12), 1664-1669, 2005 | 432 | 2005 |
| The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies HJ Willison, CP O'leary, J Veitch, LD Blumhardt, M Busby, M Donaghy, ... Brain 124 (10), 1968-1977, 2001 | 310 | 2001 |
| The nature of fatigue in multiple sclerosis H Ford, P Trigwell, M Johnson Journal of psychosomatic research 45 (1), 33-38, 1998 | 262 | 1998 |
| Health status and quality of life of people with multiple sclerosis H L. Ford, E. Gerry, MH Johnson, A. Tennant Disability and rehabilitation 23 (12), 516-521, 2001 | 202 | 2001 |
| Developing a disease-specific quality of life measure for people with multiple sclerosis HL Ford, E Gerry, A Tennant, D Whalley, R Haigh, MH Johnson Clinical Rehabilitation 15 (3), 247-258, 2001 | 156 | 2001 |
| Clinical presentation and diagnosis of multiple sclerosis H Ford Clinical Medicine 20 (4), 380, 2020 | 112 | 2020 |
| Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial J Chataway, F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, ... The Lancet Neurology 19 (3), 214-225, 2020 | 111 | 2020 |
| Screening for the risk of job loss in multiple sclerosis (MS): development of an MS-specific Work Instability Scale (MS-WIS) E McFadden, MC Horton, HL Ford, G Gilworth, M McFadden, A Tennant Multiple Sclerosis Journal 18 (6), 862-870, 2012 | 107 | 2012 |
| Multiple sclerosis and pregnancy AR Lorenzi, HL Ford Postgraduate medical journal 78 (922), 460-464, 2002 | 76 | 2002 |
| A prospective study of the incidence, prevalence and mortality of multiple sclerosis in Leeds HL Ford, E Gerry, M Johnson, R Williams Journal of neurology 249, 260-265, 2002 | 68 | 2002 |
| The prevalence of multiple sclerosis in the Leeds Health Authority HL Ford, E Gerry, CM Airey, A Vail, MH Johnson, DRR Williams Journal of Neurology, Neurosurgery & Psychiatry 64 (5), 605-610, 1998 | 63 | 1998 |
| Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment O Lily, E McFadden, E Hensor, M Johnson, H Ford Multiple Sclerosis Journal 12 (6), 808-813, 2006 | 60 | 2006 |
| Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing … P Connick, F De Angelis, RA Parker, D Plantone, A Doshi, N John, ... BMJ open 8 (8), e021944, 2018 | 54 | 2018 |
| Multiple sclerosis: it epidemiological, genetic, and health care impact. R Williams, AS Rigby, M Airey, M Robinson, H Ford Journal of epidemiology and community health 49 (6), 563, 1995 | 54 | 1995 |
| Use of coping strategies in multiple sclerosis: Association with demographic and disease-related characteristics✰ DP Holland, DK Schlüter, CA Young, RJ Mills, DJ Rog, HL Ford, ... Multiple sclerosis and related disorders 27, 214-222, 2019 | 51 | 2019 |
| Social determinants of health in multiple sclerosis R Dobson, DR Rice, M D’hooghe, R Horne, Y Learmonth, FJ Mateen, ... Nature Reviews Neurology 18 (12), 723-734, 2022 | 42 | 2022 |
| A systematic review of discrete-choice experiments and conjoint analysis studies in people with multiple sclerosis EJD Webb, D Meads, I Eskyte, N King, N Dracup, J Chataway, HL Ford, ... The Patient-Patient-Centered Outcomes Research 11, 391-402, 2018 | 38 | 2018 |
| Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy CA Young, R Mills, D Rog, B Sharrack, T Majeed, CS Constantinescu, ... Journal of the neurological sciences 426, 117437, 2021 | 36 | 2021 |
Alan TennantLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK.Verified email at leeds.ac.uk
